Supplementary Figure S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading

Supplementary Figure S5 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the murine CT26 (KRAS G12C-mutant) model.